Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pedi-cRIB in Relapsed Pediatric B-Cell ALL
NCT05645718Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2023
- Primary completion
- Dec 2027
- Modality
- scFv Fragments, Monoclonal Antibodies, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of rituximab, inotuzumab ozogamicin and blinatumomab in B cell acute lymphoblastic leukemia (B-ALL) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of Adverse Events and Complete Response Rate. Started Jul 2023; status: recruiting.
02
Drugs
rituximabinotuzumab ozogamicinblinatumomab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT05645718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05645718.